AI Cancer Detection Risks Outpace Ethical Safeguards, but the Fix Is Voluntary Guidance

The FDA's January 2025 draft guidance on AI-enabled medical devices recommends bias analysis and lifecycle management—but as voluntary guidance, not binding rules. Once an algorithm is cleared, there is no federal requirement that manufacturers report how it performs across racial, ethnic, or geographic subgroups after deployment. This creates a blind spot: women with dense breast tissue and patients from historically marginalized groups can experience higher error rates from automated cancer screening without any regulatory mechanism to detect or correct it.

Supporters of stronger oversight point to the Algorithmic Accountability Act, which would require companies using automated decision systems to conduct impact assessments. As of the 119th Congress, the bill has been introduced in the U.S. House as H.R. 5511 (Congress.gov). A Senate companion bill—sometimes referenced as S. 2164—is not verifiable in available congressional records as of the date of this writing. Neither version has advanced out of committee. The progressive alternative is to close the post-market monitoring gap: mandate real-world demographic performance reporting for all FDA-authorized AI devices, provide a right of redress for patients harmed by diagnostic errors, and integrate equity audits into federal procurement that Medicare and Medicaid could extend through coverage decisions. Until then, a cancer missed by an algorithm remains a market failure—not a regulatory one.